ClinicalTrials.gov
ClinicalTrials.gov Menu

The ONE Study UK Treg Trial (ONETreg1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02129881
Recruitment Status : Unknown
Verified June 2014 by Guy's and St Thomas' NHS Foundation Trust.
Recruitment status was:  Recruiting
First Posted : May 2, 2014
Last Update Posted : June 20, 2014
Sponsor:
Collaborator:
King's College London
Information provided by (Responsible Party):
Guy's and St Thomas' NHS Foundation Trust

Brief Summary:
A study to assess cell therapy as a treatment to prevent kidney transplant rejection. The trial will involve purification of naturally occurring regulatory T cells (nTregs) from living-donor renal transplant recipients. The cells will then be grown in the laboratory and re‐infused into the patient five days after the kidney transplant. This trial is part of an international European Union funded consortium aimed at evaluating cellular immunotherapy in solid organ transplantation (The ONE Study). It is anticipated that immune regulation induced by nTreg therapy can eventually be used to recude the need for conventional immunosuppression in transplant recipients.

Condition or disease Intervention/treatment Phase
End-stage Renal Failure Biological: Autologous regulatory T Cell Product Phase 1 Phase 2

Detailed Description:
Decades of immunosuppressive drug development has produced an array of powerful pharmacological agents, but the various drawbacks with these treatments leaves considerable room for improvement. By harnessing the power of suppressive mechanisms in the human immune system, regulatory cell therapy may be able to support peripheral tolerance and induce a level of donor-specific unresponsiveness that allows for a reduction in the use of conventional immunosuppression in organ transplant recipients. Several alternative regulatory cell types have been identified as potential adjunct immunotherapies for solid organ transplantation and are now approaching a stage of development that would allow clinical testing in an early-stage trial. The EU-funded international ONE study consortium aims to answer the question as to whether Treg treatment, or other immunoregulatory cell-based therapies, can be advanced in the clinical management of solid organ transplant recipients. This particular Treg trial aims to explored the potential of Treg therapy as an adjunct immunosuppressive treatment in living-donor renal transplant recipients through a clinical protocol design shared by other investigators in the ONE study group testing additional regulatory cell therapies in seperate trials.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation
Study Start Date : April 2014
Estimated Primary Completion Date : December 2016
Estimated Study Completion Date : March 2017

Arm Intervention/treatment
Experimental: Autologous regulatory T Cell Product

Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed below:

Prednisolone Day 0: 500 mg IV (250mg pre‐op, 250mg intra‐op) Day 1: 125 mg IV Day 2 to 14: 20.0 mg/day oral Week 3 to 4: 15.0 mg/day oral Week 5 to 8: 10.0 mg/day oral Week 9 to 12: 5.0 mg/day oral Week 13 to 14: 2.5 mg/day oral Week 15 to End: Cessation Mycophenolate Mofetil (MMF) Day ‐7 to ‐2: 500 mg/day oral Day ‐1 to 14: 2000 mg/day oral Week 3 to 36: 1000 mg/day oral Week 37 to 40: 750 mg/day oral Week 41 to 44: 500 mg/day oral Week 45 to 48: 250 mg/day oral Week 49 to End: Cessation Tacrolimus Day ‐4 to 14: 3‐12 ng/ml oral Week 3 to 12: 3‐10 ng/ml oral Week 13 to 36: 3‐8 ng/ml oral Week 37 to End: 3‐6 ng/ml oral

Biological: Autologous regulatory T Cell Product
Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed in the arm description.




Primary Outcome Measures :
  1. Incidence of biopsy‐confirmed acute rejection. [ Time Frame: 60 weeks ]

Secondary Outcome Measures :
  1. Time to first acute rejection episode [ Time Frame: 60 weeks ]
  2. Severity of acute rejection episodes [ Time Frame: 60 weeks ]
  3. Total immunosuppressive burden [ Time Frame: 60 weeks ]
  4. Incidence of chronic graft dysfunction [ Time Frame: 60 weeks ]
  5. Incidence of graft loss through rejection [ Time Frame: 60 weeks ]
  6. Incidence of adverse drug reactions [ Time Frame: 60 weeks ]
  7. Incidence of major and/or opportunistic infections [ Time Frame: 60 weeks ]
  8. Incidence of neoplasia. [ Time Frame: 60 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Recipient Inclusion Criteria

  1. Chronic renal insufficiency necessitating kidney transplantation and approved to receive a primary kidney allograft from a living donor
  2. Aged at least 18 years
  3. Able to commence the immunosuppressive regimen at the protocol‐specified time point
  4. Willing and able to participate in The ONE Study IM and HEC subprojects
  5. Signed and dated written informed consent

Exclusion Criteria

  1. Patient has previously received any tissue or organ transplant
  2. Known contraindication to the protocol‐specified treatments / medications
  3. Genetically identical to the prospective organ donor at the HLA loci (0‐0‐0 mismatch)
  4. PRA grade > 40% within 6 months prior to enrolment
  5. Previous treatment with any desensitisation procedure (with or without IVIg)
  6. Concomitant malignancy or history of malignancy within 5 years prior to planned study entry (excluding successfully‐treated non‐metastatic basal/squamous cell carcinoma of the skin)
  7. Evidence of significant local or systemic infection
  8. EBV‐negative; serologically positive for anti‐HIV‐1,2; HBsAg; Anti‐HBc; Anti‐HCV‐ab; Anti‐HTLV‐1,2 or syphilis (Treponema palladium)
  9. Significant liver disease, defined as persistently elevated AST and/or ALT levels > 2 x ULN (Upper Limit of Normal range)
  10. Malignant or pre‐malignant haematological conditions
  11. Any uncontrolled medical condition or concurrent disease that could interfere with the study objectives
  12. Any condition which, in the judgement of the Investigator, would place the subject at undue risk
  13. Ongoing treatment with systemic immunosuppressive drugs at study entry
  14. Participation in another clinical trial during the study or within 28 days prior to planned study entry
  15. Female patients of child‐bearing potential with a positive pregnancy test at enrolment
  16. Female patients who are breast‐feeding
  17. All female patients of child‐bearing potential UNLESS:

    1. The patient is willing to maintain a highly effective method of birth control for the duration of the study
    2. The career, lifestyle, or sexual orientation of the patient ensures that there is no risk of pregnancy for the duration of the study (at the discretion of the Investigator)
  18. Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow‐up visit schedule
  19. Any form of substance abuse, psychiatric disorder, or other condition that, in the opinion of the Investigator, may invalidate communication with the Investigator and/or designated study personnel
  20. Patients unable to freely give their informed consent (e.g. individuals under legal guardianship).

Donor Inclusion Criteria

  1. Eligible for live kidney donation
  2. Aged at least 18 years
  3. An ABO blood type compatible with the organ recipient
  4. Willing and able to provide a blood sample for The ONE Study IM Subproject
  5. Willing to provide personal and medical/biological data for the trial analysis
  6. Signed and dated written informed consent. Exclusion Criteria

1. Genetically identical to the prospective organ recipient at the HLA loci (0‐0‐0 mismatch) 2. Exposure to any investigational agents at the time of kidney donation, or within 28 days prior to kidney donation 3. Any form of substance abuse, psychiatric disorder, or other condition that, in the opinion of the Investigator, may invalidate communication with the Investigator designated study personnel 4. Subjects unable to freely give their informed consent (e.g. individuals under legal guardianship)


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02129881


Contacts
Contact: Rachel Hilton, BMBCh, PhD rachel.hilton@gstt.nhs.uk

Locations
United Kingdom
Guy's Hospital Recruiting
London, United Kingdom, SE1 9RT
Principal Investigator: David Game, PhD MRCP         
The Oxford Transplant Centre - Churchill Hospital Recruiting
Oxford, United Kingdom, OX3 7LE
Principal Investigator: Paul Harden, MB.Ch.B.         
Sponsors and Collaborators
Guy's and St Thomas' NHS Foundation Trust
King's College London
Investigators
Study Director: Giovanna Lombardi, PhD King's College Hospital NHS Trust

Additional Information:
Responsible Party: Guy's and St Thomas' NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT02129881     History of Changes
Other Study ID Numbers: ONETreg1
First Posted: May 2, 2014    Key Record Dates
Last Update Posted: June 20, 2014
Last Verified: June 2014

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Failure, Chronic
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Mycophenolic Acid
Prednisolone
Antibiotics, Antineoplastic
Antineoplastic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal